secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001770787-23-000051
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance
--------------------------------------------------------------------------------

- Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.
- Gross margin fell to 62% from 77% YoY due to product mix from Xenium instrument placements.
- Operating loss $94.8M ($40.0M prior year); includes $41.4M in-process R&D and $40.2M stock comp.
- Net loss $93.0M vs $41.9M; cash & securities $356.9M as of Sep 30.
- Xenium platform driving demand; launched new panel configurations and Beckman Coulter partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/0001770787-23-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/txg-20231102.htm
  HTML page:      https://secwatch.observer/filing/0001770787-23-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer